New Enterprise Associates 16, L.p. - Net Worth and Insider Trading

New Enterprise Associates 16, L.p. Net Worth

The estimated net worth of New Enterprise Associates 16, L.p. is at least $285 Million dollars as of 2024-11-29. New Enterprise Associates 16, L.p. is the 10% Owner of Mirum Pharmaceuticals Inc and owns about 4,186,243 shares of Mirum Pharmaceuticals Inc (MIRM) stock worth over $195 Million. New Enterprise Associates 16, L.p. is the 10% Owner of Akouos Inc and owns about 4,294,207 shares of Akouos Inc (AKUS) stock worth over $57 Million. New Enterprise Associates 16, L.p. is also the 10% Owner of Trevi Therapeutics Inc and owns about 10,421,428 shares of Trevi Therapeutics Inc (TRVI) stock worth over $29 Million. Besides these, New Enterprise Associates 16, L.p. also holds Marker Therapeutics Inc (MRKR) , Metacrine Inc (MTCR) , Genocea Biosciences Inc (GNCAQ) . Details can be seen in New Enterprise Associates 16, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that New Enterprise Associates 16, L.p. has not made any transactions after 2022-05-25 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of New Enterprise Associates 16, L.p.

New Enterprise Associates 16, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, New Enterprise Associates 16, L.p. owns 10 companies in total, including Metacrine Inc (MTCR) , Genocea Biosciences Inc (GNCAQ) , and Akouos Inc (AKUS) among others .

Click here to see the complete history of New Enterprise Associates 16, L.p.’s form 4 insider trades.

Insider Ownership Summary of New Enterprise Associates 16, L.p.

Ticker	Comapny	Transaction Date	Type of Owner
MTCR	Metacrine Inc	2021-12-22	10 percent owner
GNCAQ	Genocea Biosciences Inc	2022-05-25	10 percent owner
AKUS	Akouos Inc	2020-06-30	10 percent owner
		2022-04-11	10 percent owner
		2020-01-29	10 percent owner
		2017-07-24	10 percent owner
		2019-07-22	10 percent owner
		2021-03-16	10 percent owner
		2017-11-20	10 percent owner
		2018-01-19	10 percent owner

New Enterprise Associates 16, L.p. Latest Holdings Summary

New Enterprise Associates 16, L.p. currently owns a total of 6 stocks. Among these stocks, New Enterprise Associates 16, L.p. owns 4,186,243 shares of Mirum Pharmaceuticals Inc (MIRM) as of July 22, 2019, with a value of $195 Million and a weighting of 68.48%. New Enterprise Associates 16, L.p. owns 4,294,207 shares of Akouos Inc (AKUS) as of June 30, 2020, with a value of $57 Million and a weighting of 20.01%. New Enterprise Associates 16, L.p. also owns 10,421,428 shares of Trevi Therapeutics Inc (TRVI) as of April 11, 2022, with a value of $29 Million and a weighting of 10.31%. The other 3 stocks Marker Therapeutics Inc (MRKR) , Metacrine Inc (MTCR) , Genocea Biosciences Inc (GNCAQ) have a combined weighting of 1.2% among all his current holdings.

Latest Holdings of New Enterprise Associates 16, L.p.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
MIRM	Mirum Pharmaceuticals Inc	2019-07-22	4,186,243	46.65	195,288,236
AKUS	Akouos Inc	2020-06-30	4,294,207	13.29	57,070,011
TRVI	Trevi Therapeutics Inc	2022-04-11	10,421,428	2.82	29,388,427
MRKR	Marker Therapeutics Inc	2021-03-16	1,071,429	3.19	3,417,859
MTCR	Metacrine Inc	2021-12-22	2,563,257	0.00	3,589
GNCAQ	Genocea Biosciences Inc	2022-05-25	0	0.00	0

Holding Weightings of New Enterprise Associates 16, L.p.

New Enterprise Associates 16, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, New Enterprise Associates 16, L.p. has made a total of 0 transactions in Mirum Pharmaceuticals Inc (MIRM) over the past 5 years. The most-recent trade in Mirum Pharmaceuticals Inc is the acquisition of 450,000 shares on July 22, 2019, which cost New Enterprise Associates 16, L.p. around $7 Million.

According to the SEC Form 4 filings, New Enterprise Associates 16, L.p. has made a total of 1 transactions in Akouos Inc (AKUS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Akouos Inc is the acquisition of 588,235 shares on June 30, 2020, which cost New Enterprise Associates 16, L.p. around $10 Million.

According to the SEC Form 4 filings, New Enterprise Associates 16, L.p. has made a total of 2 transactions in Trevi Therapeutics Inc (TRVI) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Trevi Therapeutics Inc is the acquisition of 2,631,578 shares on April 11, 2022, which cost New Enterprise Associates 16, L.p. around $5 Million.

More details on New Enterprise Associates 16, L.p.'s insider transactions can be found in the Insider Trading History of New Enterprise Associates 16, L.p. table.

Insider Trading History of New Enterprise Associates 16, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

New Enterprise Associates 16, L.p. Trading Performance

GuruFocus tracks the stock performance after each of New Enterprise Associates 16, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by New Enterprise Associates 16, L.p. is -0.54%. GuruFocus also compares New Enterprise Associates 16, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by New Enterprise Associates 16, L.p. within 3 months outperforms 3 times out of 9 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how New Enterprise Associates 16, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of New Enterprise Associates 16, L.p.

Average Return

Average return per transaction

Outperforming Transactions

1 out of 9 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-0.28
Relative Return to S&P 500(%)	-1.83

New Enterprise Associates 16, L.p. Ownership Network

Ownership Network List of New Enterprise Associates 16, L.p.

No Data

Ownership Network Relation of New Enterprise Associates 16, L.p.

New Enterprise Associates 16, L.p. Owned Company Details

What does Metacrine Inc do?

Who are the key executives at Metacrine Inc?

New Enterprise Associates 16, L.p. is the 10 percent owner of Metacrine Inc. Other key executives at Metacrine Inc include Chief Business Officer Michael York , director & President & CEO Preston Klassen , and 10 percent owner Braden Michael Leonard .

Metacrine Inc (MTCR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Metacrine Inc (MTCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Metacrine Inc (MTCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Metacrine Inc (MTCR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Metacrine Inc Insider Transactions

No Available Data

What does Genocea Biosciences Inc do?

Who are the key executives at Genocea Biosciences Inc?

New Enterprise Associates 16, L.p. is the 10 percent owner of Genocea Biosciences Inc. Other key executives at Genocea Biosciences Inc include CHIEF LEGAL & COMPLIANCE OFF Jacquelyn L Sumer , director & President and CEO William D Clark , and CHIEF FINANCIAL OFFICER Diantha Duvall .

Genocea Biosciences Inc (GNCAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Genocea Biosciences Inc (GNCAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Genocea Biosciences Inc (GNCAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Genocea Biosciences Inc (GNCAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Genocea Biosciences Inc Insider Transactions

No Available Data

What does Akouos Inc do?

Who are the key executives at Akouos Inc?

New Enterprise Associates 16, L.p. is the 10 percent owner of Akouos Inc. Other key executives at Akouos Inc include 10 percent owner Kearny Acquisition Corp , 10 percent owner Lilly Eli & Co , and Chief Operating Officer Jennifer Anne Wellman .

Akouos Inc (AKUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Akouos Inc (AKUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akouos Inc (AKUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Akouos Inc (AKUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Akouos Inc Insider Transactions

No Available Data

What does Trevi Therapeutics Inc do?

Who are the key executives at Trevi Therapeutics Inc?

New Enterprise Associates 16, L.p. is the 10 percent owner of Trevi Therapeutics Inc. Other key executives at Trevi Therapeutics Inc include director & 10 percent owner & See Remarks Jennifer L Good , director & 10 percent owner David P Meeker , and 10 percent owner & Chief Medical Officer Thomas Sciascia .

Trevi Therapeutics Inc (TRVI) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 16, L.p. made no insider transaction in Trevi Therapeutics Inc (TRVI). Other recent insider transactions involving Trevi Therapeutics Inc (TRVI) include a net sale of 7,825 shares made by Lisa Delfini , a net sale of 90,795 shares made by Jennifer L Good , and a net sale of 101,369 shares made by Thomas Sciascia .

In summary, during the past 3 months, insiders sold 61,180 shares of Trevi Therapeutics Inc (TRVI) in total and bought 0 shares, with a net sale of 61,180 shares. During the past 18 months, 204,544 shares of Trevi Therapeutics Inc (TRVI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 204,544 shares.

Trevi Therapeutics Inc (TRVI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Trevi Therapeutics Inc Insider Transactions

No Available Data

What does Black Diamond Therapeutics Inc do?

Who are the key executives at Black Diamond Therapeutics Inc?

New Enterprise Associates 16, L.p. is the 10 percent owner of Black Diamond Therapeutics Inc. Other key executives at Black Diamond Therapeutics Inc include 10 percent owner Versant Venture Capital Vi, L.p. , 10 percent owner Biotech Growth N V , and director & 10 percent owner Ali Behbahani .

Black Diamond Therapeutics Inc (BDTX) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 16, L.p. made no insider transaction in Black Diamond Therapeutics Inc (BDTX). Other recent insider transactions involving Black Diamond Therapeutics Inc (BDTX) include a net purchase of 3,140,000 shares made by Biotech Growth N V , a net purchase of 1,000,000 shares made by Ali Behbahani , and a net purchase of 935,850 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 0 shares of Black Diamond Therapeutics Inc (BDTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 246,600 shares of Black Diamond Therapeutics Inc (BDTX) were sold and 5,075,850 shares were bought by its insiders, resulting in a net purchase of 4,829,250 shares.

Black Diamond Therapeutics Inc (BDTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Black Diamond Therapeutics Inc Insider Transactions

No Available Data

What does Regulus Therapeutics Inc do?

Who are the key executives at Regulus Therapeutics Inc?

New Enterprise Associates 16, L.p. is the 10 percent owner of Regulus Therapeutics Inc. Other key executives at Regulus Therapeutics Inc include Chief Financial Officer Crispina Calsada , Sr. VP & General Counsel Christopher Ray Aker , and Chief Operating Officer Joseph P Hagan .

Regulus Therapeutics Inc (RGLS) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 16, L.p. made no insider transaction in Regulus Therapeutics Inc (RGLS). Other recent insider transactions involving Regulus Therapeutics Inc (RGLS) include a net sale of 14,580 shares made by Joseph P Hagan , a net sale of 5,468 shares made by Crispina Calsada , and a net sale of 5,468 shares made by Christopher Ray Aker .

In summary, during the past 3 months, insiders sold 0 shares of Regulus Therapeutics Inc (RGLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 25,516 shares of Regulus Therapeutics Inc (RGLS) were sold and 4,000 shares were bought by its insiders, resulting in a net sale of 21,516 shares.

Regulus Therapeutics Inc (RGLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Regulus Therapeutics Inc Insider Transactions

No Available Data

What does Mirum Pharmaceuticals Inc do?

Who are the key executives at Mirum Pharmaceuticals Inc?

New Enterprise Associates 16, L.p. is the 10 percent owner of Mirum Pharmaceuticals Inc. Other key executives at Mirum Pharmaceuticals Inc include SVP & Global Controller Jolanda Howe , director & 10 percent owner Patrick J Heron , and Chief Scientific Officer Pamela Vig .

Mirum Pharmaceuticals Inc (MIRM) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 16, L.p. made no insider transaction in Mirum Pharmaceuticals Inc (MIRM). Other recent insider transactions involving Mirum Pharmaceuticals Inc (MIRM) include a net sale of 11,012 shares made by Jolanda Howe , a net purchase of 162,308 shares made by Patrick J Heron , and a net sale of 34,606 shares made by Pamela Vig .

In summary, during the past 3 months, insiders sold 2,500 shares of Mirum Pharmaceuticals Inc (MIRM) in total and bought 345 shares, with a net sale of 2,155 shares. During the past 18 months, 108,350 shares of Mirum Pharmaceuticals Inc (MIRM) were sold and 176,308 shares were bought by its insiders, resulting in a net purchase of 67,958 shares.

Mirum Pharmaceuticals Inc (MIRM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mirum Pharmaceuticals Inc Insider Transactions

No Available Data

What does Marker Therapeutics Inc do?

Who are the key executives at Marker Therapeutics Inc?

New Enterprise Associates 16, L.p. is the 10 percent owner of Marker Therapeutics Inc. Other key executives at Marker Therapeutics Inc include Interim CFO Eliot M Lurier , 10 percent owner Mohamad Makhzoumi , and 10 percent owner Carmen Chang .

Marker Therapeutics Inc (MRKR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Marker Therapeutics Inc (MRKR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Marker Therapeutics Inc (MRKR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Marker Therapeutics Inc (MRKR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Marker Therapeutics Inc Insider Transactions

No Available Data

What does X4 Pharmaceuticals Inc do?

Who are the key executives at X4 Pharmaceuticals Inc?

New Enterprise Associates 16, L.p. is the 10 percent owner of X4 Pharmaceuticals Inc. Other key executives at X4 Pharmaceuticals Inc include director & President and CEO Paula Ragan , Chief Scientific Officer Arthur Taveras , and Chief Operating Officer Mary Dibiase .

X4 Pharmaceuticals Inc (XFOR) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 16, L.p. made no insider transaction in X4 Pharmaceuticals Inc (XFOR). Other recent insider transactions involving X4 Pharmaceuticals Inc (XFOR) include a net sale of 633,780 shares made by Paula Ragan , a net sale of 161,480 shares made by Mary Dibiase , and a net sale of 552,345 shares made by Adam S. Mostafa .

In summary, during the past 3 months, insiders sold 692,259 shares of X4 Pharmaceuticals Inc (XFOR) in total and bought 0 shares, with a net sale of 692,259 shares. During the past 18 months, 1,658,682 shares of X4 Pharmaceuticals Inc (XFOR) were sold and 25,000 shares were bought by its insiders, resulting in a net sale of 1,633,682 shares.

X4 Pharmaceuticals Inc (XFOR)'s detailed insider trading history can be found in Insider Trading Tracker table.

X4 Pharmaceuticals Inc Insider Transactions

No Available Data

What does Genocea Biosciences Inc do?

Who are the key executives at Genocea Biosciences Inc?

New Enterprise Associates 16, L.p. is the 10 percent owner of Genocea Biosciences Inc. Other key executives at Genocea Biosciences Inc include CHIEF LEGAL & COMPLIANCE OFF Jacquelyn L Sumer , EVP PHARM SCI & MFG Stapleton Raymond D Jr , and 10 percent owner Paul Edward Walker .

Genocea Biosciences Inc (GGNNQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Genocea Biosciences Inc (GGNNQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Genocea Biosciences Inc (GGNNQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Genocea Biosciences Inc (GGNNQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Genocea Biosciences Inc Insider Transactions

No Available Data

New Enterprise Associates 16, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for New Enterprise Associates 16, L.p.. You might contact New Enterprise Associates 16, L.p. via mailing address: 1954 Greenspring Drive, Suite 600, Timonium Md 21093.

Discussions on New Enterprise Associates 16, L.p.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.